NKGen Biotech Korea

엔케이젠바이오텍코리아KRX: 182400· Fiscal year 2025· nkmax.com ↗

Average salary
Not disclosed
Employees
70
▼ 4.1% vs 2024
Average tenure
8.3 yrs

Reference: average annual pay in Healthcare & Pharma, South Korea: $31.4K (고용노동부 사업체노동력조사 2025 (KOSIS DT_118N_MON052), 2025). Official government wage statistics for the whole industry, not this company's pay. Definitions differ by country; see the source.

Workplace

Women's pay (men = 100)85
Women among staff62.9%
Contract staff0%

Recent official filings

Quick read

  • Headcount shrank by 3 (4.1%) from 2024.
  • Revenue fell 10.7% year over year.
  • Revenue has shrunk two years in a row.
  • Operating loss of $1.9M in 2025.

Last 3 years

Revenue
$7.5M2023$6.6M2024$5.9M2025
Operating income
-$50.7M2023-$3.1M2024-$1.9M2025

See the share price on Naver Finance ↗

Investor metrics

2025
Revenue per employee
$84.1K
Net profit per employee
-$78.5K
Operating margin
-32.2%
Net margin
-93.4%
ROE
-103.5%
Debt-to-equity
101.5%
Equity ratio
49.6%

Per-employee figures use the company headcount, so they run high for groups with many subsidiaries. Not investment advice.

USD at ₩1,332.22 per $1 (2026-11-19, ExchangeRate-API)

Source: DART (Financial Supervisory Service, Korea)

Not investment advice. Figures come from public filings and may contain errors.